Literature DB >> 19596891

The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently.

Robert Gelber1, Koen Andries, Rose Maria D Paredes, Cora Evelyn S Andaya, Jasmin Burgos.   

Abstract

The diarylquinoline R207910 is profoundly bactericidal in a murine model of tuberculosis. Previously, R207910 was also found to be bactericidal for Mycobacterium leprae-infected mice during lag phase. Herein we evaluate the bactericidal efficacy of R207910 (1 to 120 mg/kg of body weight) when administered five times weekly, once weekly, and once monthly during logarithmic multiplication of M. leprae organisms. All treatments were found to be bactericidal, suggesting that both low and intermittent dosing with R207910 holds promise for leprosy patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596891      PMCID: PMC2737847          DOI: 10.1128/AAC.00722-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice.

Authors:  R H Gelber; P Siu; M Tsang; L P Murray
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility.

Authors:  Eric Nuermberger; Denis A Mitchison
Journal:  Am J Respir Crit Care Med       Date:  2009-01-01       Impact factor: 21.405

4.  In vitro and in vivo activities of macrolides against Mycobacterium leprae.

Authors:  S G Franzblau; R C Hastings
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

5.  Activity of minocycline in Mycobacterium leprae-infected mice.

Authors:  R H Gelber
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

6.  Rapid bactericidal effect of rifampin on Mycobacterium leprae.

Authors:  C C Shepard; L Levy; P Fasal
Journal:  Am J Trop Med Hyg       Date:  1972-07       Impact factor: 2.345

7.  The killing of Mycobacterium leprae in mice by various dietary concentrations of clofazimine and ethionamide.

Authors:  R H Gelber
Journal:  Lepr Rev       Date:  1987-12       Impact factor: 0.537

8.  A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation.

Authors:  C C Shepard
Journal:  Lepr Rev       Date:  1981-12       Impact factor: 0.537

9.  Activity of ofloxacin against Mycobacterium leprae in the mouse.

Authors:  J H Grosset; C C Guelpa-Lauras; E G Perani; C Beoletto
Journal:  Int J Lepr Other Mycobact Dis       Date:  1988-06

10.  Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse.

Authors:  C C Guelpa-Lauras; E G Perani; A M Giroir; J H Grosset
Journal:  Int J Lepr Other Mycobact Dis       Date:  1987-03
View more
  6 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

Review 3.  Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

Authors:  Stephen K Field
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

4.  A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis.

Authors:  Gregory J Fox; Dick Menzies
Journal:  Infect Dis Ther       Date:  2013-08-02

Review 5.  Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.

Authors:  Iram Khan Iqbal; Sapna Bajeli; Ajit Kumar Akela; Ashwani Kumar
Journal:  Pathogens       Date:  2018-02-23

6.  World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.

Authors:  Maria Lazo-Porras; Gabriela J Prutsky; Patricia Barrionuevo; Jose Carlos Tapia; Cesar Ugarte-Gil; Oscar J Ponce; Ana Acuña-Villaorduña; Juan Pablo Domecq; Celso De la Cruz-Luque; Larry J Prokop; Germán Málaga
Journal:  BMC Infect Dis       Date:  2020-01-20       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.